Appeals Court Reinstates Glaxo $235.5 Million Verdict Against Teva

A federal appeals court on Friday reinstated a 2017 jury verdict ordering Teva Pharmaceutical Industries Ltd. to pay GlaxoSmithKline Plc $235.5 million for selling a generic version of Glaxo’s heart drug Coreg. In a 2-1 decision, the U.S. Federal Circuit …

from News – Insurance Journal